Document Detail


Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
MedLine Citation:
PMID:  23030295     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiotensin II receptor blockers (ARBs) inhibit the renin-angiotensin system. As a result, these agents provide beneficial effects in terms of cardiovascular (CV) and renal protection, independent of their blood pressure-lowering effects. Telmisartan and valsartan are the most intensively studied ARBs for the effects on CV outcomes. Randomized clinical trials assessing morbidity and mortality end points have included a range of patient types, including those with hypertension, hypertension with Type 2 diabetes, high CV risk without hypertension, ischemic heart disease, stroke and heart failure. Few head-to-head comparisons between telmisartan and valsartan have been performed. However, some blood pressure-independent properties of these two ARBs can be scrutinized from separate studies in the available literature.
Authors:
Massimo Volpe
Related Documents :
3449745 - Effect of hypoxia and adenosine on the microvascular reserve in the rabbit heart.
1705755 - Resistance of ascending vasa recta to transport of water.
7363175 - Perfusion in cardioplegia: an experimental study.
7922865 - Characterization of perfused periaortic brown adipose tissue from the rat.
3169955 - Pulmonary diffusion capacity for co at varying alveolar oxygen tensions and different a...
10912755 - Lack of association between a biallelic polymorphism in the adducin gene and blood pres...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  10     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-10-03     Completed Date:  2013-02-27     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1061-72     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 2 Receptor Blockers / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Benzimidazoles / adverse effects,  therapeutic use*
Benzoates / adverse effects,  therapeutic use*
Cardiovascular Diseases / complications,  etiology,  prevention & control*
Diabetes Mellitus, Type 2 / complications,  physiopathology
Evidence-Based Medicine
Humans
Hypertension / complications,  drug therapy,  physiopathology
Tetrazoles / adverse effects,  therapeutic use*
Valine / adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Angiotensin II Type 2 Receptor Blockers; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Benzoates; 0/Tetrazoles; 137862-53-4/valsartan; HG18B9YRS7/Valine; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coronary heart disease in Type 2 diabetes: mechanisms and comprehensive prevention strategies.
Next Document:  Expression of NOX5 in human teratozoospermia compared to normozoospermia.